Exclusively, they said Congress only supposed person service fees to be compensated on new indications for just a new Lively component and that switching a drug to more than-the-counter position was an exception to your rule necessitating user fees.[ten]seven. Adjustments to Pre-Approval and Article-Acceptance Postmarketing Requirements (PMRs) Comm